A scaffold hopping strategy was successfully applied in discovering 2-aminooxazole amides as potent DGAT1 inhibitors for the treatment of dyslipidemia. Further optimization in potency and PK properties resulted in a lead series with oral in vivo efficacy in a mouse postprandial triglyceridemia (PPTG) assay.
Keywords: DGAT1 inhibitors; Scaffold hopping; Treatment for dyslipidemia.
Copyright © 2013 Elsevier Ltd. All rights reserved.